BeiGene Ltd. ADR | Mutual Funds
Mutual Funds that own BeiGene Ltd. ADR
Fidelity Growth Company Fund
2,032,477
3.44%
-11,029
0.74%
07/31/2018
Canada Pension Plan
995,000
1.68%
995,000
0.05%
03/31/2018
Fidelity Series Growth Company Fund
576,636
0.98%
0
0.77%
07/31/2018
T Rowe Price Health Sciences Fund
488,615
0.83%
-4,772
0.68%
06/30/2018
Hartford Mid Cap Fund
470,674
0.8%
0
0.63%
07/31/2018
Fidelity Select Health Care Portfolio
463,300
0.78%
0
1.08%
07/31/2018
Vanguard Emerging Markets Stock Index Fund
458,782
0.78%
-3,430
0.1%
07/31/2018
Oppenheimer International Small Company Fund
450,370
0.76%
-237,280
0.76%
02/28/2018
iShares Nasdaq Biotechnology ETF
428,573
0.73%
-5,607
0.78%
09/06/2018
T Rowe Price New Horizons Fund
426,897
0.72%
-6,600
0.31%
06/30/2018
| Address |
Zhongguancun Life Science Park
Beijing Beijing 102206
China
|
|
Employees
|
- |
| Website |
http://www.beigene.com |
| Updated |
07/08/2019 |
| BeiGene Ltd. is a commercial-stage biopharmaceutical company, which engages in the development and commercialization of innovative molecularly targeted and immuno-oncology drugs for the treatment of cancer. It focuses on Zanubrutinib (BGB-3111), Tislelizumab (BGB-A317), and Pamiparib (BGB-290). The company was founded by Xiao Dong Wang and John V. |
